These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37803394)

  • 1. The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities.
    Macé C; Nikiema JB; Sarr OS; Ciza Hamuli P; Marini RD; Neci RC; Bourdillon Esteve P; Ravinetto R
    J Pharm Policy Pract; 2023 Oct; 16(1):117. PubMed ID: 37803394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention, Detection and Response to incidences of substandard and falsified medical products in the Member States of the Southern African Development Community.
    Kniazkov S; Dube-Mwedzi S; Nikiema JB
    J Pharm Policy Pract; 2020; 13():71. PubMed ID: 33088577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.
    Pisani E; Nistor AL; Hasnida A; Parmaksiz K; Xu J; Kok MO
    Wellcome Open Res; 2019; 4():70. PubMed ID: 31131333
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review.
    Asrade Mekonnen B; Getie Yizengaw M; Chanie Worku M
    J Pharm Policy Pract; 2024; 17(1):2375267. PubMed ID: 39015754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.
    Pisani E; Hasnida A; Rahmi M; Kok MO; Harsono S; Anggriani Y
    JMIR Public Health Surveill; 2021 Aug; 7(8):e29309. PubMed ID: 34181563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems.
    Chabalenge B; Jere E; Nanyangwe N; Hikaambo C; Mudenda S; Banda M; Kalungia A; Matafwali S
    J Med Access; 2022; 6():27550834221141767. PubMed ID: 36601496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substandard and falsified medicines in African pharmaceutical markets: A case study from Ethiopia.
    Mengesha A; Bastiaens H; Ravinetto R; Gibson L; Dingwall R
    Soc Sci Med; 2024 May; 349():116882. PubMed ID: 38669893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa.
    Kusynová Z; Bais Y; van den Ham HA; Mantel-Teeuwisse AK; Etame-Loe G; Kaale E; Sarr SO; Guiet-Mati F; Bourdillon-Esteve P
    BMJ Glob Health; 2023 Feb; 6(Suppl 3):. PubMed ID: 36731919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The capacity of young national medicine regulatory authorities to ensure the quality of medicines: case of Rwanda.
    Shabani JBB; Kayitare E; Nyirimigabo E; Habyalimana V; Murindahabi MM; Ntirenganya L; Irasabwa C; Rutungwa E; Munyangaju JE; Hahirwa I
    J Pharm Policy Pract; 2022 Nov; 15(1):90. PubMed ID: 36434730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substandard and falsified medical products are a global public health threat. A pilot survey of awareness among physicians in Sweden.
    Funestrand H; Liu R; Lundin S; Troein M
    J Public Health (Oxf); 2019 Mar; 41(1):e95-e102. PubMed ID: 29860331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Health alerts for substandard, falsified, and unregistered medical products at the onset of the COVID-19 pandemic in the AmericasAlertas de saúde para produtos médicos abaixo do padrão, falsificados e não registrados no início da pandemia de COVID-19 nas Américas].
    Gorordo M; Rojas-Cortés R; Carino J; Vahos Zambrano J; Castro JL
    Rev Panam Salud Publica; 2024; 48():e7. PubMed ID: 38370134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The scourge of substandard and falsified medical products gets worse with COVID-19 pandemic.
    Shiferie F; Kassa E
    Pan Afr Med J; 2020; 37():344. PubMed ID: 33738032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving access to medicines to reduce marketing and use of substandard and falsified medicines in Africa: Scoping review.
    Sorato MM; Davari M; Kebriaeezadeh A
    J Med Access; 2024; 8():27550834241236598. PubMed ID: 38476401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing health system strengthening through improving access to medicines: A review of local manufacturing policies in Ghana.
    Peprah Boaitey K; Tuck C
    Med Access Point Care; 2020; 4():2399202620962299. PubMed ID: 36204087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study.
    Higgins CR; Kobia B; Ozawa S
    PLoS One; 2023; 18(1):e0268661. PubMed ID: 36652447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.